Winton Group’s Vor Biopharma VOR Stock Holding History

Winton Group’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,870	Closed	-$212K	–	1520
2026 Q1	$212K	Buy	+11,870	New	+$167K	0.01%	967

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Winton Group's VOR Position: Q2 2026 in Review

Winton Group sold out of Vor Biopharma (VOR) in Q2 2026, closing a stake of 11,870 shares — an estimated $212K sold.

Winton Group first reported a position in VOR in Q1 2026 and held it in 1 quarter. The position peaked at $212K in Q1 2026. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Winton Group reported no remaining Vor Biopharma position as of Q2 2026 after selling out during the quarter.
Winton Group sold 11,870 Vor Biopharma shares in Q2 2026, an estimated $212K.
Winton Group first reported a position in Vor Biopharma in Q1 2026 and held it in 1 quarter.
Winton Group's Vor Biopharma position peaked at $212K in Q1 2026.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.